Pedigrees of cases carrying the R214C and G153D mutations.

<p>(A) R214C: African-American proband diagnosed with stage IIA, ER/PR positive, Her2/Neu positive, infiltrating ductal carcinoma of the breast at age 42 years. (B) G153D: Non-Hispanic Caucasian proband diagnosed with breast cancer at age 60 years and with stage IV, serous carcinoma of the ovary at age 79 years.</p

Characteristics of tested individual in family.

<p>Characteristics of tested individual in family.</p

Immunoblots of <i>RAD51C</i> in the yeast strains used for the two-hybrid analysis

<p>. The <i>upper panel</i> shows the immunoblot blot analysis of the yeast strains containing human XRCC3 and RAD51C while the <i>lower panel</i> shows the same immunoblots from the yeast strains used in the RAD51B and RAD51C analysis. The RAD51C-Gal4 fusion peptides were identified using an anti-Gal4 monoclonal antibody. The same lysates were probed with an antibody against β-actin as a control for equal loading of protein.</p

Effect of <i>RAD51C</i> point mutations on the interaction with XRCC3 and RAD51B.

<p>(A) Yeast two-hybrid assays were performed with XRCC3 in the DNA-binding domain vector and either wild-type or site-specifically mutated <i>RAD51C</i> in the activating domain vector. (B) Yeast two-hybrid assays were performed with RAD51B in the DNA-binding domain vector and the <i>RAD51C</i> variants in the activating domain vector. Results from liquid ONPG assays are the average of 5–7 different transformants performed in triplicate, with the standard error of the mean. * : <i>P</i><0.05 and ** :<i>P</i>≤0.001 using the student <i>T</i>-test.</p